<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00939458</url>
  </required_header>
  <id_info>
    <org_study_id>1087/06</org_study_id>
    <nct_id>NCT00939458</nct_id>
  </id_info>
  <brief_title>Study of Lamotrigine 2 x 25 mg IR Tablets of Torrent Pharmaceuticals Pvt., Ltd., India and Lamictal ® (Lamotrigine) 2 x 25 mg Tablets of Glaxo-SmithKline, USA, in Healthy Human Adult Subjects, Under Fed Conditions</brief_title>
  <official_title>A Randomized, Open Label, Single Dose, Crossover, Bioequivalence Study of Lamotrigine 2 x 25 mg IR Tablets of Torrent Pharmaceuticals Pvt., Ltd., India and Lamictal ® (Lamotrigine) 2 x 25 mg Tablets of Glaxo-SmithKline, USA, in Healthy Human Adult Subjects,Under Fed Conditions</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Torrent Pharmaceuticals Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Torrent Pharmaceuticals Limited</source>
  <brief_summary>
    <textblock>
      -  Objective:

             -  To assess the bioequivalence of Lamotrigine 2 x 25 mg IR tablets of Torrent
                Pharmaceuticals Pvt., Ltd., India and Lamictal ® (Lamotrigine) 2 x 25 mg tablets of
                Glaxo-SmithKline, USA, in healthy human adult subjects, under fed conditions.

        -  Study Design:

             -  A randomized, open label, two treatment, two period, two sequence, single dose,
                crossover study, under fed conditions.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <primary_outcome>
    <measure>Bioequivalence</measure>
  </primary_outcome>
  <condition>Healthy</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lamotrigine</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy adult subjects of either sex between 18-55 years of age (inclusive), having a
             body mass index (BMI) between 18 and 27 kg/m2

          -  Subjects who have no evidence of underlying disease during screening and whose
             physical examination is performed within 21 days prior to commencement of the study.

          -  Subjects whose screening laboratory values are within normal limits or values outside
             normal limits considered by the physician/Principal Investigator to be of no clinical
             significance.

          -  Informed consent given in written form according to section 11.3 of the protocol.

          -  Female Subjects:

               1. of child bearing potential practicing an acceptable method of birth control for
                  the duration of the study as judged by the investigator(s), such as condoms,
                  foams, jellies, diaphragm, intrauterine device (IUD), or abstinence.

               2. postmenopausal for at least 1 year.

               3. surgically sterile (bilateral tubal ligation, bilateral oophorectomy, or
                  hysterectomy has been performed on the subject)

        Exclusion Criteria:

          -  Cardiovascular, pulmonary, hepatic, renal, hematological, gastrointestinal, endocrine,
             immunologic, dermatologic, musculoskeletal, neurological or psychiatric disease.

          -  Alcohol dependence, alcohol abuse or drug abuse within past one year.

          -  Moderate to heavy smoking (&gt; 10 cigarettes/day) or consumption of tobacco products.

          -  History of difficulty in swallowing tablet.

          -  Clinically significant illness within 4 weeks before the start of the study

          -  Asthma, urticaria or other allergic type reactions after taking any medication.

          -  Positive urine drug screening, HIV, Hepatitis B &amp; C tests.

          -  Any history of hypersensitivity to Lamotrigine.

          -  Existence of any surgical or medical condition, which, in the judgment of clinical
             investigator might interfere with the pharmacokinetics of the drug or likely to
             compromise the safety of the subject.

          -  Inability to communicate or co-operate with the investigator due to language problem,
             attitude, poor mental development/impaired cerebral function.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
  </eligibility>
  <location>
    <facility>
      <name>Lotus Labs Pvt. Ltd.</name>
      <address>
        <city>Bangalore</city>
        <state>Karnataka</state>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 13, 2009</study_first_submitted>
  <study_first_submitted_qc>July 14, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 15, 2009</study_first_posted>
  <last_update_submitted>October 23, 2017</last_update_submitted>
  <last_update_submitted_qc>October 23, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 25, 2017</last_update_posted>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lamotrigine</mesh_term>
    <mesh_term>Anticonvulsants</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

